If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account. If the address matches an existing account you will receive an email with instructions to retrieve your username.
Skip to Main Content. Burckart PharmD, Fadi G. Lakkis MD,. First published: 20 April About this book This comprehensive reference source will benefit all transplant specialists working with pharmacologic and biologic agents that modulate the immune system. Compiled by a team of world-renowned editors and contributors covering the fields of transplantation, nephrology, pharmacology, and immunology, the book covers all anti-rejection drugs according to a set template and includes the efficacy of each for specific diseases.
Export Citation s. Export Citation. Plain Text.
Join Kobo & start eReading today
Citation file or direct import. For help, please view the citation help. Citation Help. Cancel Export. Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance.
Types of Bone Marrow Transplant & Cancer Immunotherapy
Hepatology ; 67 : — Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. J Hepatol ; 64 : — Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma. Hepatology ; 69; — Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation.
Cancer ; 68 : — Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg ; : — Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol ; 59 : — Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol ; 19 : — Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?
Transl Gastroenterol Hepatol ; 2 : Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant ; 19 : — Immunomodulating therapy in liver transplantation: principles and practice. Immunotherapy ; 4 : — Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation?
Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study.
- Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines!
- California Penal Code 2011;
- Sword of Rome: Pharsalus.
- The Daisy Boys Club (Book One / The Early Years 1)?
- Unique is What We Are.
Transplantation ; 80 Suppl. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol ; 11 : — Zheng Y, Jiang Y. Mol Cell Pharmacol ; 7 : 15— Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation ; 89 : — Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc ; 40 : — Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: month results of a randomized multicenter study.
Am J Transplant ; 18 : — Nishida N, Kudo M. Immunological microenvironment of hepatocellular carcinoma and its clinical implication. Oncology ; 92 Suppl. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res ; 15 : — Int J Cancer ; : — Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest ; : — PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity. Nature ; : — Immunological landscape and immunotherapy of hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol ; 12 : — Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol ; 10 : Liver stem cells and hepatocellular carcinoma. Hepatology ; 49 : — Concise Reviews: cancer stem cell targeted therapies: toward clinical success.
- Adaptive Immunotherapy for Opportunistic Infections.
- Scammers Among Us Beware: Scams and Fraud;
- The Step-Dad Dilemmas;
Stem Cells Transl Med. Epub ahead of print 17 October DOI: Nat Commun ; 9 : Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses.
Nat Rev Cancer ; 18 : — Gut microbiota of liver transplantation recipients. Sci Rep ; 7 : Longitudinal analysis of the intestinal microbiota in liver transplantation. Transplant Direct ; 3 : e Ren Z, Li a, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
Epub ahead of print 25 July Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Gut microbiome influences efficacy of PDbased immunotherapy against epithelial tumors.
- Join Kobo & start eReading today.
- THE BEAUTY WE FEAR: THE GREAT MOSQUES OF THE WORLD.
- Cases in the literature.
- Adaptive Immunotherapy for Opportunistic Infections | SpringerLink.
- Portals II, Battle in the Skies (The Portals Trilogy Book 2).
Science ; : 91— Schramm C. Bile Acids, the microbiome, immunity, and liver tumors. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer ; 19; — Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science ; : 97— Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
Immunol Rev ; : — Nat Biotechnol ; 36 : — Programmed cell death-1 PD-1 checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD Hepatology ; 66 : — Adaptor protein DOK3 promotes plasma cell differentiation by regulating the expression of programmed cell death 1 ligands.
PD-1 shapes B cells as evildoers in the tumor microenvironment. Cancer Discov ; 6 : — Am J Transplant ; 13 : — J Exp Med ; : — Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant ; 14 : 59— Tumor and microenvironment evolution during immunotherapy with Nivolumab.
Cell ; : — Phase I study of single-agent anti-programmed death-1 MDX in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol ; 28 : — Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer ; 4 : Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity.
ESMO Open ; 3 : e Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant ; 16 : — PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol ; : — Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.
Cancer immunotherapy in patients with new or recurrent malig : IJS Oncology
Pediatr Blood Cancer ; 64 : e Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. Cancer Treat Rev ; 63 : — Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J ; 6 : — Ford ML. T cell cosignaling molecules in transplantation. Immunity ; 44 : — Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol ; 15; — Differential location and distribution of hepatic immune cells.
Cells ; 6 : E Immunotherapy for hepatocellular carcinoma: current advances and future expectations. J Immunol Res ; : Front Immunol ; 9 : Cell Immunol ; : 64— Profiling immunologic risk for acute rejection in liver transplantation: recipient age is an important risk factor.
Transpl Immunol ; 38 : 44— Clinical factors affecting rejection rates in liver transplantation. Hepatobiliary Pancreat Dis Int ; 14 : —